Korting H C, Blecher P, Fröschl M, Braun-Falco O
Department of Dermatology, Ludwig-Maximilians University, Munich, Germany.
Mycoses. 1992 Jul-Aug;35(7-8):173-6. doi: 10.1111/j.1439-0507.1992.tb00840.x.
Fifteen male patients with manifest oral candidosis due to Candida albicans, suffering from AIDS-related complex (ARC) or full-blown AIDS, were investigated both clinically and microbiologically before and about 1 and 4 weeks after 7 to 10 days of treatment with 200 mg ketoconazole p.o. per day. Candida albicans was quantitated in mouthwash fluid. The antimicrobial susceptibility of the Candida albicans isolates was assessed using the IC30 test. In the short term, clinical cure was obtained in 87%, mycological cure in 53%. In the long term, the corresponding figures were 56 and 9%, respectively. Eradication of Candida albicans was not possible if IC30 values exceeded 256 micrograms ml-1. While pretreatment counts of Candida albicans in those patients also taking zidovudine did not differ from those in the rest of the study population, both the clinical and the mycological efficacy of ketoconazole seem to be higher both in the short and the long term when administered together with zidovudine. In consideration of the high relapse rate after about 4 weeks, an interval treatment protocol with oral ketoconazole is proposed.
对15名因白色念珠菌导致明显口腔念珠菌病、患有艾滋病相关综合征（ARC）或完全型艾滋病的男性患者，在口服每天200毫克酮康唑治疗7至10天之前、治疗后约1周和4周时进行了临床和微生物学调查。对漱口液中的白色念珠菌进行定量。使用IC30试验评估白色念珠菌分离株的抗菌敏感性。短期内，87%的患者获得临床治愈，53%的患者获得真菌学治愈。长期来看，相应数字分别为56%和9%。如果IC30值超过256微克/毫升，则不可能根除白色念珠菌。虽然同时服用齐多夫定的患者白色念珠菌的治疗前计数与研究人群中其他患者的计数没有差异，但酮康唑与齐多夫定联合给药时，短期和长期的临床和真菌学疗效似乎都更高。考虑到约4周后的高复发率，提出了口服酮康唑的间歇治疗方案。
